Enterprise Value

430.7M

Cash

146.7M

Avg Qtr Burn

-16.77M

Short % of Float

5.66%

Insider Ownership

5.95%

Institutional Own.

87.48%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Govorestat (AT-007) Details
Galactosemia, Rare diseases, Rare genetic disease

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Govorestat (AT-007) Details
Sorbitol dehydrogenase deficiency

Phase 3

Update

Caficrestat (AT-001) Details
Hemophilia, Genetic disorder, Diabetic cardiomyopathy

Phase 3

Update

Govorestat (AT-007) Details
Phosphomannomutase 2 deficiency , Congenital disorder of glycosylation

Phase 2

Update

AT-003 Details
Diabetic retinopathy

Phase 1

Update

AT-104 Details
Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma

Failed

Discontinued